Cardiff Oncology, Inc. announced on June 17, 2025, the appointment of Roger Sidhu, MD, as its new Chief Medical Officer. Dr. Sidhu brings over 20 years of oncology leadership and clinical experience, with a proven track record in advancing innovative therapies through late-stage clinical development. He previously served as Chief Medical Officer and acting CEO at Treadwell Therapeutics and held significant roles at Amgen, including leading Phase 3 clinical trials for panitumumab in mCRC.
Dr. Sidhu succeeds Dr. Fairooz Kabbinavar, who will transition to an advisory role within the company. This leadership change is expected to guide onvansertib through its next phase of development, particularly as the company prepares for registrational trials. In connection with his appointment, Dr. Sidhu was granted non-qualified stock options to purchase 600,000 shares of Cardiff Oncology common stock.
Concurrently, Cardiff Oncology announced its plan to share additional clinical data from the ongoing randomized Phase 2 CRDF-004 trial in first-line RAS-mutated mCRC on July 29, 2025. The company expects to release a substantive dataset at this time, providing a critical update on its lead program. This specific date provides investors with a clear upcoming catalyst for the company's stock.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.